← Back to patent-cliff list
Onfasprodil
Tier C — Watch / tradeOnfasprodil
Novartis
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：NMDAR2B
Indications (approved)：Treatment-resistant depression, Major depressive disorder
Regional status
US
Phase II
2021-07-20
EU
Phase II
2021-07-20
China
-
Japan
Phase II
2021-07-20
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Onfasprodil?
Approved indications include: Treatment-resistant depression, Major depressive disorder.
When does the Onfasprodil patent expire?
No public expiry year is available for Onfasprodil yet; this page updates once verified.
How do I get a quote for Onfasprodil intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21